High-throughput sequencing of chemosensitive small cell lung cancer cell lines H82 and DMS114, and their corresponding chemoresistant counterparts

Small cell lung cancer (SCLC) is the most aggressive subtype of lung cancer. Although most patients are initially sensitive to first-line chemotherapy with combined cisplatin and etoposide, chemotherapy drug resistance easily develops and quickly leads to tumor progression. Therefore, understanding the mechanisms of chemotherapy drug resistance and how to reverse it is key to improving the prognosis of patients with SCLC. The parental SCLC cell lines H82 and DMS114, along with their corresponding cisplatin-induced resistant counterparts (H82DDP and DMS114DDP), were used to explore the mechanisms of chemoresistance in SCLC.